Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
12548
Shown on this page
12
Current sort
Recently updated
Location scope
Miami, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Miami, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 505–516 of 12,548 matching trials in Miami, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Not applicable Interventional

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

NCT05080673
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
45 Years to 70 Years
Enrollment
9,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2065
U.S. locations
484
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 328 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Enrolling by invitation Phase 3 Interventional

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

NCT06194799
View directory record Official record
Conditions
Alzheimer's Disease Psychosis
Interventions
ACP-204
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
23
States / cities
Scottsdale, Arizona • Costa Mesa, California • Fresno, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Recruiting Phase 3 Interventional

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099
View directory record Official record
Conditions
Crohn's Disease, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Recruiting Phase 1 Interventional

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NCT07300241
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic, ccRCC, VHL-Associated Clear Cell Renal Cell Carcinoma, VHL-Associated Renal Cell Carcinoma, Kidney Cancer Metastatic, Kidney Cancers
Interventions
NEO-811
Drug
Lead sponsor
Neomorph, Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Duarte, California • San Diego, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Placebo, MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
25
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Active, not recruiting Not applicable Interventional

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

NCT02921022
View directory record Official record
Conditions
Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Gemcitabine, Nab-paclitaxel, PEGPH20
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267
View directory record Official record
Conditions
Asthma
Interventions
TEV-56248, Albuterol sulfate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
4 Years and older
Enrollment
2,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
157
States / cities
Birmingham, Alabama • Dothan, Alabama • Paradise Valley, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Recruiting Phase 2 Interventional

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

NCT07029581
View directory record Official record
Conditions
Lewy Body Dementia Psychosis
Interventions
ACP-204, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 84 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
31
States / cities
Irvine, California • Aurora, Colorado • Washington D.C., District of Columbia + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Recruiting Phase 2 Interventional

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

NCT07269210
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Solbinsiran, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Recruiting Phase 2 Interventional

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099
View directory record Official record
Conditions
Crohn Disease
Interventions
LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
63
States / cities
Arcadia, California • Coronado, California • Lancaster, California + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST
Recruiting Phase 1 Interventional

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

NCT07213791
View directory record Official record
Conditions
Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Advanced Solid Tumors
Interventions
LY4337713
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
20
States / cities
Newport Beach, California • Stanford, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 14, 2026, 1:14 AM EST